Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma
Introduction. Endogenously produced antiganglioside antibodies could affect the evolution of cutaneous melanoma. Epidemiological and experimental evidence suggest “chronic inflammation” to be one of the hallmarks in skin cancers. The aim of the study was to characterize the relation between antigang...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/2491265 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561459428589568 |
|---|---|
| author | Corina Daniela Ene Mircea Tampa Ilinca Nicolae Cristina Iulia Mitran Madalina Irina Mitran Clara Matei Ana Caruntu Constantin Caruntu Simona Roxana Georgescu |
| author_facet | Corina Daniela Ene Mircea Tampa Ilinca Nicolae Cristina Iulia Mitran Madalina Irina Mitran Clara Matei Ana Caruntu Constantin Caruntu Simona Roxana Georgescu |
| author_sort | Corina Daniela Ene |
| collection | DOAJ |
| description | Introduction. Endogenously produced antiganglioside antibodies could affect the evolution of cutaneous melanoma. Epidemiological and experimental evidence suggest “chronic inflammation” to be one of the hallmarks in skin cancers. The aim of the study was to characterize the relation between antiganglioside antibodies and inflammation in cutaneous melanoma focusing on gangliosides GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b. Material and Method. We performed an observational study that included 380 subjects subdivided into three groups: patients with metastatic melanoma (170 cases), patients with primary melanoma (160 cases), and healthy subjects (50 subjects). The assessment of antiganglioside antibodies, IgG, and IgM classes, against -GM1, -GM2, -GM3, -GD1a, -GD1b, -GT1b, -GQ1b was performed using immunoblot technique (EUROLine kit). Results. The presence of IgG and IgM antiganglioside antibodies in primary melanoma was (%), as follows: anti-GM1 (5.0 and 13.1), -GM2 (1.8 and 18.1), -GM3 (0.6 and 5.6), -GD1a (0.6 and 15.0), -GD1b (3.7 and 10.7), -GT1b (0.0 and 13.1), -GQ1b (0.0 and 5.0). In metastatic melanoma, the level of antiganglioside antibodies was significantly lower compared with primary melanoma (p<0.05), while in the control group they were absent. Antiganglioside antibodies anti-GM1 and -GD1a were positively correlated, while anti-GM3, -GD1b, and -GT1b were negatively associated with the inflammatory markers, interleukin 8 (IL-8), and C reactive protein (CRP). Conclusions. Tumour ganglioside antigens generate an immune response in patients with primary melanomas. The host’s ability to elaborate an early antiganglioside response could be considered as a defence mechanism, directed toward eliminating a danger signal from the tumour microenvironment. Antiganglioside antibodies associated with inflammation markers could be used as diagnostic, monitoring, and treatment tools in patients with cutaneous melanoma. |
| format | Article |
| id | doaj-art-cb2113e1258b480da783979b36ed78b0 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-cb2113e1258b480da783979b36ed78b02025-02-03T01:24:56ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/24912652491265Antiganglioside Antibodies and Inflammatory Response in Cutaneous MelanomaCorina Daniela Ene0Mircea Tampa1Ilinca Nicolae2Cristina Iulia Mitran3Madalina Irina Mitran4Clara Matei5Ana Caruntu6Constantin Caruntu7Simona Roxana Georgescu8“Carol Davila” Nephrology Hospital, 4 Calea Grivitei, 010731 Bucharest, Romania“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021 Bucharest, Romania“Victor Babes” Clinical Hospital for Infectious Diseases, 281 Mihai Bravu, 030303 Bucharest, Romania“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021 Bucharest, Romania“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021 Bucharest, Romania“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021 Bucharest, RomaniaDepartment of Oral and Maxillofacial Surgery, “Carol Davila” Central Military Emergency Hospital, 134 Calea Plevnei, 010825 Bucharest, Romania“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021 Bucharest, Romania“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021 Bucharest, RomaniaIntroduction. Endogenously produced antiganglioside antibodies could affect the evolution of cutaneous melanoma. Epidemiological and experimental evidence suggest “chronic inflammation” to be one of the hallmarks in skin cancers. The aim of the study was to characterize the relation between antiganglioside antibodies and inflammation in cutaneous melanoma focusing on gangliosides GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b. Material and Method. We performed an observational study that included 380 subjects subdivided into three groups: patients with metastatic melanoma (170 cases), patients with primary melanoma (160 cases), and healthy subjects (50 subjects). The assessment of antiganglioside antibodies, IgG, and IgM classes, against -GM1, -GM2, -GM3, -GD1a, -GD1b, -GT1b, -GQ1b was performed using immunoblot technique (EUROLine kit). Results. The presence of IgG and IgM antiganglioside antibodies in primary melanoma was (%), as follows: anti-GM1 (5.0 and 13.1), -GM2 (1.8 and 18.1), -GM3 (0.6 and 5.6), -GD1a (0.6 and 15.0), -GD1b (3.7 and 10.7), -GT1b (0.0 and 13.1), -GQ1b (0.0 and 5.0). In metastatic melanoma, the level of antiganglioside antibodies was significantly lower compared with primary melanoma (p<0.05), while in the control group they were absent. Antiganglioside antibodies anti-GM1 and -GD1a were positively correlated, while anti-GM3, -GD1b, and -GT1b were negatively associated with the inflammatory markers, interleukin 8 (IL-8), and C reactive protein (CRP). Conclusions. Tumour ganglioside antigens generate an immune response in patients with primary melanomas. The host’s ability to elaborate an early antiganglioside response could be considered as a defence mechanism, directed toward eliminating a danger signal from the tumour microenvironment. Antiganglioside antibodies associated with inflammation markers could be used as diagnostic, monitoring, and treatment tools in patients with cutaneous melanoma.http://dx.doi.org/10.1155/2020/2491265 |
| spellingShingle | Corina Daniela Ene Mircea Tampa Ilinca Nicolae Cristina Iulia Mitran Madalina Irina Mitran Clara Matei Ana Caruntu Constantin Caruntu Simona Roxana Georgescu Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma Journal of Immunology Research |
| title | Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma |
| title_full | Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma |
| title_fullStr | Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma |
| title_full_unstemmed | Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma |
| title_short | Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma |
| title_sort | antiganglioside antibodies and inflammatory response in cutaneous melanoma |
| url | http://dx.doi.org/10.1155/2020/2491265 |
| work_keys_str_mv | AT corinadanielaene antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma AT mirceatampa antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma AT ilincanicolae antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma AT cristinaiuliamitran antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma AT madalinairinamitran antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma AT claramatei antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma AT anacaruntu antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma AT constantincaruntu antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma AT simonaroxanageorgescu antigangliosideantibodiesandinflammatoryresponseincutaneousmelanoma |